In the same way that molecularly targeted therapies have transformed decision making of many diseases, advances in nuclear medicine and molecular imaging are poised to re-invent the way in which we diagnose, stage, and monitor response to therapy in patients with prostate cancer. Several next-generation imaging (NGI) modalities facilitate an improved diagnostic accuracy for the staging of prostate cancer, especially at lower tumour burdens. In view of these new imaging modalities, the American Society of Clinical Oncology (ASCO) recently formulated recommendations on how to appropriately use these techniques in different prostate cancer subgroups. During BMUC 2021, Prof. Anwar Padhani talked us through the key take home messages of these guidelines.
